Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 12—December 2018
Research

Capnocytophaga canimorsus Capsular Serovar and Disease Severity, Helsinki Hospital District, Finland, 2000–2017

Estelle Hess1, Francesco Renzi1, Panu Karhunen1, Mélanie Dol, Adrien Lefèvre, Jenni Antikainen, Elodie Carlier, Johanna Hästbacka2, and Guy R. Cornelis2Comments to Author 
Author affiliations: University of Namur, Namur, Belgium (E. Hess, F. Renzi, M. Dol, A. Lefèvre, E. Carlier, G.R. Cornelis); University of Eastern Finland, Kuopio, Finland (P. Karhunen); University of Helsinki and Helsinki University Hospital, Helsinki, Finland (J. Antikainen, J. Hästbacka)

Main Article

Table 3

Coagulation and fibrinolysis laboratory variables, by Capnocytophaga canimorsus serovar and disease severity, Helsinki, Finland, 2000–2017*

Variable Reference range Serovar
 p value Severity of illness
 p value
A, n = 17 B, n = 28 C, n = 22 Severe, n = 25 Mild, n = 45
Platelets, 109/L 150–360 109 (29–137) [2] 109 (28–140) [1] 93 (23–166) [1] 0.98 23 (9.5–89) [0] 117 (95–154.3) [4] <0.001
PTT, %† 70–130 56 (24–71) [10] 78 (56–86) [11] 58 (44.5–75) [12] 0.284 54 (39–66) [2] 87 (70.5–109.5) [31] <0.001
FiDD, mg/L <0.5 47.9 (5.05–83.8) [12] 9.1 (3.4–85.7) [19] 14.5 (4.1–80.7) [15] 0.888 32.9 (5.6–81) [5] 1.6 (0.6–74.7) [40] 0.057

*Values are given as median (interquartile range) [no. missing values] except as indicated. The comparison between patients with mild and severe courses of disease was defined by the level of care they needed. Patients with mild disease were those who were treated in a regular ward or the emergency department, and patients with severe disease were those treated in high surveillance or intensive care units. FiDD, fibrin D-dimers; PTT, partial thromboplastin time.
†PTT was analyzed according to the Owren method (8). PTT was calculated as the ratio of the result (in seconds) from normal plasma to the result (in seconds) from the patient sample x 100.

Main Article

References
  1. Butler  T. Capnocytophaga canimorsus: an emerging cause of sepsis, meningitis, and post-splenectomy infection after dog bites. Eur J Clin Microbiol Infect Dis. 2015;34:1271–80. DOIPubMedGoogle Scholar
  2. Butler  T, Weaver  RE, Ramani  TK, Uyeda  CT, Bobo  RA, Ryu  JS, et al. Unidentified gram-negative rod infection. A new disease of man. Ann Intern Med. 1977;86:1–5. DOIPubMedGoogle Scholar
  3. Pers  C, Gahrn-Hansen  B, Frederiksen  W. Capnocytophaga canimorsus septicemia in Denmark, 1982-1995: review of 39 cases. Clin Infect Dis. 1996;23:71–5. DOIPubMedGoogle Scholar
  4. van Dam  AP, Jansz  A. Capnocytophaga canimorsus infections in The Netherlands: a nationwide survey. Clin Microbiol Infect. 2011;17:312–5. DOIPubMedGoogle Scholar
  5. Hästbacka  J, Hynninen  M, Kolho  E. Capnocytophaga canimorsus bacteremia: clinical features and outcomes from a Helsinki ICU cohort. Acta Anaesthesiol Scand. 2016;60:1437–43. DOIPubMedGoogle Scholar
  6. Renzi  F, Ittig  SJ, Sadovskaya  I, Hess  E, Lauber  F, Dol  M, et al. Evidence for a LOS and a capsular polysaccharide in Capnocytophaga canimorsus. Sci Rep. 2016;6:38914. DOIPubMedGoogle Scholar
  7. Hess  E, Renzi  F, Koudad  D, Dol  M, Cornelis  GR. Identification of virulent Capnocytophaga canimorsus isolates by capsular typing. J Clin Microbiol. 2017;55:1902–14. DOIPubMedGoogle Scholar
  8. Owren  PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet. 1959;2:754–8. DOIPubMedGoogle Scholar
  9. Tissari  P, Zumla  A, Tarkka  E, Mero  S, Savolainen  L, Vaara  M, et al. Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet. 2010;375:224–30. DOIPubMedGoogle Scholar
  10. Renzi  F, Dol  M, Raymackers  A, Manfredi  P, Cornelis  GR. Only a subset of C. canimorsus strains is dangerous for humans. Emerg Microbes Infect. 2016;5:e29. DOIPubMedGoogle Scholar
  11. Mally  M, Shin  H, Paroz  C, Landmann  R, Cornelis  GR. Capnocytophaga canimorsus: a human pathogen feeding at the surface of epithelial cells and phagocytes. PLoS Pathog. 2008;4:e1000164. DOIPubMedGoogle Scholar
  12. Manfredi  P, Renzi  F, Mally  M, Sauteur  L, Schmaler  M, Moes  S, et al. The genome and surface proteome of Capnocytophaga canimorsus reveal a key role of glycan foraging systems in host glycoproteins deglycosylation. Mol Microbiol. 2011;81:1050–60. DOIPubMedGoogle Scholar
  13. Renzi  F, Manfredi  P, Mally  M, Moes  S, Jenö  P, Cornelis  GR. The N-glycan glycoprotein deglycosylation complex (Gpd) from Capnocytophaga canimorsus deglycosylates human IgG. PLoS Pathog. 2011;7:e1002118. DOIPubMedGoogle Scholar
  14. Suzuki  M, Kimura  M, Imaoka  K, Yamada  A. Prevalence of Capnocytophaga canimorsus and Capnocytophaga cynodegmi in dogs and cats determined by using a newly established species-specific PCR. Vet Microbiol. 2010;144:172–6. DOIPubMedGoogle Scholar

Main Article

1These first authors contributed equally to this article.

2These authors were co–principal investigators.

Page created: November 19, 2018
Page updated: November 19, 2018
Page reviewed: November 19, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external